These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20563581)

  • 41. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma.
    Rodgers LT; Lester McCully CM; Odabas A; Cruz R; Peer CJ; Figg WD; Warren KE
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):827-830. PubMed ID: 31894347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice.
    Tan SY; Kan E; Lim WY; Chay G; Law JH; Soo GW; Bukhari NI; Segarra I
    J Pharm Pharmacol; 2011 Jul; 63(7):918-25. PubMed ID: 21635257
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
    Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
    Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates.
    Warren KE; Patel MC; McCully CM; Montuenga LM; Balis FM
    Cancer Chemother Pharmacol; 2000; 45(3):207-12. PubMed ID: 10663638
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HPLC-APCI-MS/MS method for the determination of catalpol in rat plasma and cerebrospinal fluid: application to an in vivo pharmacokinetic study.
    Wang Q; Xing M; Chen W; Zhang J; Qi H; Xu X
    J Pharm Biomed Anal; 2012 Nov; 70():337-43. PubMed ID: 22677654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex) in a nonhuman primate model.
    Widemann BC; Balis FM; Godwin KS; McCully C; Adamson PC
    Cancer Chemother Pharmacol; 1999; 44(6):439-43. PubMed ID: 10550563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
    Zhuang Y; Fraga CH; Hubbard KE; Hagedorn N; Panetta JC; Waters CM; Stewart CF
    Cancer Res; 2006 Dec; 66(23):11305-13. PubMed ID: 17145877
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates.
    Berg SL; Bonate PL; Nuchtern JG; Dauser R; McGuffey L; Bernacky B; Blaney SM
    Clin Cancer Res; 2005 Aug; 11(16):5981-3. PubMed ID: 16115942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates.
    Heideman RL; Balis FM; McCully C; Poplack DG
    Cancer Res; 1988 Aug; 48(15):4294-8. PubMed ID: 2455594
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate.
    Berg SL; Murry DJ; McCully CL; Godwin K; Balis FM
    Clin Cancer Res; 1998 Nov; 4(11):2891-4. PubMed ID: 9829757
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate.
    Berg S; Serabe B; Aleksic A; Bomgaars L; McGuffey L; Dauser R; Durfee J; Nuchtern J; Blaney S
    Cancer Chemother Pharmacol; 2001 May; 47(5):385-90. PubMed ID: 11391852
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.
    Freeman BB; Iacono LC; Panetta JC; Gajjar A; Stewart CF
    Neuro Oncol; 2006 Apr; 8(2):89-95. PubMed ID: 16461424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Gender on the Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4/6 for the Treatment of Cancer, in Rats.
    Mudunuru J; Ren C; Taft DR; Maniar M
    Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):531-538. PubMed ID: 30701428
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
    Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats.
    Kapetanovic IM; Muzzio M; McCormick DL; Thompson TN; Johnson WD; Horn TL; Mohammed A; Rao CV; Kopelovich L
    Cancer Chemother Pharmacol; 2012 May; 69(5):1301-6. PubMed ID: 22302406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The plasma pharmacokinetics and cerebral spinal fluid penetration of intravenous topiramate in newborn pigs.
    Galinkin JL; Kurth CD; Shi H; Priestley MA; Loepke AW; Adamson PC
    Biopharm Drug Dispos; 2004 Sep; 25(6):265-71. PubMed ID: 15334626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates.
    Blaney SM; Daniel MJ; Harker AJ; Godwin K; Balis FM
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2779-82. PubMed ID: 8593019
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
    Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
    Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
    [TBL] [Abstract][Full Text] [Related]  

  • 60. LC-MS/MS method for quantitation of the CK2 inhibitor silmitasertib (CX-4945) in human plasma, CSF, and brain tissue, and application to a clinical pharmacokinetic study in children with brain tumors.
    Zhong B; Campagne O; Salloum R; Purzner T; Stewart CF
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122254. PubMed ID: 32615532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.